Partners with South Korea’s Kai Health, launches AI-powered Vita Embryo across Nova’s 120 clinics in 65 cities
Bangalore, August 21, 2025: Nova IVF Fertility, India’s fastest-growing fertility chain, has announced the integration of Artificial Intelligence (AI) into its IVF labs to bring in greater precision and trust to embryo selection, an extremely crucial element of fertility treatment. The fertility chain will implement Vita Embryo, an AI-based embryo assessment, across its 120 clinics in 65 cities. This is implemented through Nova IVF’s partnership with South Korea’s AI technology firm Kai Health. This technology will improve pregnancy rates, reduce time of a patient’s IVF cycle, and can bring in much better transparency in the fertility treatment.
One of the most critical moments in IVF treatment is the selection of the right embryo. Within the IVF Lab, Clinical Embryologists apply years of expertise, grading each embryo on its capacity to develop into a pregnancy. With Artificial Intelligence, now serving as an additional pair of eyes, this helps to further improve accuracy. Technology can spot tiny details about embryo health that might be too subtle for a human eye and can give couples added confidence that the best possible embryo is being selected for their journey.
Nova IVF Fertility is operated by Asia Healthcare Holdings – India’s only platform dedicated exclusively to single-specialty healthcare. The fertility chain performs over 20,000 IVF cycles annually across more than 120 clinics nationwide. The fertility chain has a clinical leadership of 120+ fertility specialists and 150+ embryologists. With the initial implementation of Vita Embryo already underway in 20 locations, it is expected to be adopted throughout the full network by the end of the year.
“With fertility rates declining in countries like India, 1 in 6 couples struggling to conceive, the need for precision in fertility treatment is the need of the hour. Nova IVF has always been at the forefront of implementing technology. Our IVF labs follow European standards of embryology protocols. With the usage of Artificial Intelligence, we are looking at improving the chances of successful pregnancies, and faster turnaround of the IVF cycle. Improved precision can also reduce the number of embryos needed for transfer, addressing ethical concerns related to multiple pregnancies. We believe that advanced technologies like this should be accessible to all patients in metros and tier 2 regions, without any additional monetary charges,” said Mr. Shobhit Agarwal, CEO, Nova IVF Fertility.
Dr. Hyejun Lee, CEO of Kai Health, said, “Our research indicates that with the intervention of AI, the precision of selecting embryos increased by 12%. Our association with Nova IVF Fertility signifies our readiness for global market expansion. We shall continue to focus on technological excellence and clinical impact by partnering with leading IVF networks globally.”
Kai Health attained medical device certification for Vita Embryo in Europe, Singapore, Korea, and India. Clinical tests indicate that AI-powered Vita Embryo can double the accuracy of embryo selection compared to human evaluation, providing couples with a better chance of attaining successful outcome.
Key Highlights:
- AI and Big data play a big role in providing highly accurate analysis
- A survey conducted by Artificial Intelligence’ s efficacy by Kai Health also indicated how the precision of selecting embryos increased by 12%
- This can save a lot of time for patients undergoing IVF treatment as embryo selection is faster
- Transparency to patients/ couples
